Singzyme, a biotech startup based in Singapore, has been awarded the 2025 Golden Ticket by Amgen and NSG BioLabs. This accolade grants Singzyme a one-year residency at NSG BioLabs, complete with access to certified BSL-2 lab facilities and networking opportunities within Amgen’s scientific community. The Golden Ticket Programme, now in its fourth year, aims to support biotech startups by providing essential infrastructure, mentorship, and resources to foster the development of new therapies.
Singzyme was chosen from a competitive pool of six finalists, impressing Amgen’s internal scientific committee with its proprietary Peptide Asparaginyl Ligase platform. This innovative technology addresses significant challenges in the manufacturing of antibody-drug conjugates and other complex biologics, offering potential for safer and more efficient production of targeted therapies.
Dr Alan Russell, Vice President for Research Biologics at Amgen, praised Singzyme’s platform, stating, “Singzyme’s novel platform reflects the strong scientific thinking and innovation emerging from Singapore’s biotech sector.” Daphne Teo, CEO and Founder of NSG BioLabs, highlighted the programme’s role as a “valuable stepping stone for biotech startups at critical stages of their journey.”
Singzyme’s Chief Technology Officer, Abbas Sahili, expressed that the award validates the transformative potential of their technology, whilst CEO Wee Kiat Tan emphasised their commitment to advancing the platform towards clinical applications in oncology and beyond.
The Golden Ticket Programme has previously supported companies like Albatroz Therapeutics and VerImmune, which have leveraged the programme to further their research and expand partnerships. The initiative underscores the importance of cross-sector collaboration in accelerating biotech innovation and growth.
“`
